AIDS | acquired immunodeficiency syndrome |
BATTLE | Biomarker-based Approaches of Targeted Therapy for Lung Cancer Elimination |
BRAF | Rapidly Accelerated Fibrosarcoma (B family) |
CaBIG | cancer Biomedical Informatics Grid |
CDER | Center for Drug Evaluation and Research |
CDRH | Center for Devices and Radiological Health |
CEO | chief executive officer |
CGL | chronic granulocytic leukemia |
CITN | Cancer Immunotherapy Trials Network |
CMS | Center for Medicare & Medicaid Services |
CRADA | Cooperative Research and Development Agreement |
CTEP | Cancer Therapy Evaluation Program |
CTLA-4 | Cytotoxic T-Lymphocyte Antigen 4 |
DCE-MRI | dynamic contrast enhanced-magnetic resonance imaging |
DOJ | Department of Justice |
EGFR | epidermal growth factor receptor |
EMA | European Medicines Agency |
ER | estrogen-receptor |
FDA | Food and Drug Administration |
FNIH | Foundation for the National Institutes of Health |
FTC | Federal Trade Commission |
GSK | GlaxoSmithKline |
HER2 | human epidermal growth factor receptor 2 |
HIV | Human Immunodeficiency Virus |
HPV | human papillomavirus |
IGF | insulin-like growth factor |
IIP | instantaneous inhibitory potential |
IND | Investigational New Drug |
IP | intellectual property |
IRB | Institutional Review Board |
I-SPY TRIAL | Investigation of Serial studies to Predict Your Therapeutic Response with Imaging And moLecular analysis |
LCMV | lymphocytic choriomeningitis virus |
MAPK | mitogen-activated protein kinase |
MEK | mitogen-activated protein kinase kinase |
MET | Methylnitronitrosoguanidine-HOS (Human osteosarcoma) Transforming gene |
MTA | Material Transfer Agreement |
mTORC1 | mammalian target of rapamycin complex-1 |
NCDDG | National Cooperative Drug Discovery Groups |
NCI | National Cancer Institute |
NERF | non-exclusive royalty-free |
NIAID | National Institute of Allergy and Infectious Diseases |
NIH | National Institutes of Health |
NOD | non-obese diabetic |
OS | overall survival |
PathCR | pathological complete response |
PET | positron emission tomography |
PFS | progression-free survival |
PI3K | phosphatidylinositol 3-kinase |
PPTP | Pediatric Preclinical Testing Program |
R&D | research and development |
SOC | standard of care |
START | Standard Terms of Agreement for Research Trial |
VEGF | vascular endothelial growth factor |
